Last edition
News about
Rgenta Therapeutics Presents Preclinical Data at ASCO 2024
Rgenta Therapeutics has showcased its preclinical data at ASCO 2024 from its lead program, RGT-61159, which is being developed for the potential treatment of adenoid cystic carcinoma (ACC), colorectal cancer (CRC) and other solid tumors as well as acute myeloid leukemia (AML).
TheraNym Signs MSA with MSD for Biologics Manufacturing
Aurobindo Pharma has announced that its wholly owned subsidiary, TheraNym Biologics Private Ltd., has signed a Master Service Agreement (MSA) with Merck Sharpe & Dohme Singapore Trading (MSD).
<br />
Catalyst Oncology and Imerman Angels Announce Collaboration
Catalyst Oncology, the biotech-focused oncology CRO brand of Catalyst Clinical Research, will start a collaboration with Imerman Angels, a renowned nonprofit organization providing free, personalized one-on-one cancer support.
ModeX Signs Master Services Deal with ProBioGen to Accelerate COVID-19 Antibody Development
ProBioGen has partnered with ModeX Therapeutics an OPKO Health Company, dedicated to combating cancer and infectious diseases with cutting-edge multi-specific biologics.
TOOsonix Gets MDR CE Mark for its New Oncology and Dermatology Device
The certification allows TOOsonix to sell its flagship product, System ONE-M™, across the European Economic Area. Treatment of skin cancer and skin diseases can now be conducted in ways never before possible, providing more patient-friendly treatment than traditional procedures.
Stevanato Group Inaugurates New Plant in Cisterna di Latina
Stevanato Group has recently launched its Cisterna di Latina plant.
Sanofi Announces Complete Acquisition of Inhibrx
Sanofi has recently announced the complete acquisition of Inhibrx, Inc.
Merck Signs MoU with KAIST to Boost Scientific Research
Merck has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).
PharmaLytica 2024 Commences Successfully in Hyderabad
Informa Markets India has announced the successful commencement of the 10th edition of PharmaLytica 2024 at HITEX, Hyderabad.
Lexicon Selects Medidata to Advance First Non-Opioid Drug for Neuropathic Pain
Medidata has been chosen by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP), with the potential for LX9211 to become the first new, non-opioid drug approved for neuropathic pain in over two decades.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy